CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Zoledronic acid

Last Updated: November 29, 2007
Result type: Reports
Project Number: SR0114-000
Product Line: Reimbursement Review

Generic Name: Zoledronic acid

Brand Name: Aclasta

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Osteoporosis, postmenopausal women

Indications: Osteoporosis, postmenopausal women

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 25, 2008

Recommendation Type: List with clinical criteria and/or conditions